TITLE:
The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
Thymopentin

SUMMARY:

      Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus
      isolation. Examine the ability of thymopentin to stimulate the immune system and alter the
      clinical findings in patients infected with HIV who do not yet have AIDS.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Patients must have the following:

          -  Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.

          -  HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of
             patients' peripheral blood monocytes (PBMC) on two separate occasions.

          -  Voluntarily sign consent.

          -  Patients with HIV "wasting syndrome" are allowed.

        Prior Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  AIDS as defined by the CDC.

          -  Significant hepatic disease.

          -  Thrombocytopenia.

          -  Hypersensitivity to thymopentin.

          -  Hemophilia A or B or other hematologic disorders requiring current or previous
             administration of blood products.

          -  Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within
             30 days prior to study entry.

        Patients with the following are excluded:

          -  AIDS as defined by the CDC.

          -  Significant hepatic disease.

          -  Thrombocytopenia.

          -  Hypersensitivity to thymopentin.

          -  Hemophilia A or B or other hematologic disorders requiring current or previous
             administration of blood products.

          -  Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within
             30 days prior to study entry.

        Prior Medication:

        Excluded within 30 days of study entry:

          -  Immunomodulatory or experimental therapy.

          -  Excluded within 90 days of study entry:

          -  Zidovudine (AZT).

        Intravenous drug abuse.
      
